Group 1 - The index focuses on leading innovative drug companies in the A-share market, consisting of no more than 50 stocks involved in innovative drug research and development [3] - Since its launch, the index has experienced a valuation increase of 81.4% with a rolling price-to-earnings ratio of 54.7 times, despite a recent decline of 0.8% [4] Group 2 - The biotechnology ETF tracks the CSI Biotechnology Theme Index, which includes no more than 50 stocks in the biotechnology sector, covering areas such as gene diagnosis, biopharmaceuticals, and blood products [6] - The biotechnology index has seen a rolling price-to-earnings ratio of 60.2 times and a decline of 0.6% since its inception [6] Group 3 - The pharmaceutical ETF tracks the CSI 300 Healthcare Index, focusing on leading companies in the healthcare sector, including chemical pharmaceuticals, medical services, and medical devices [7] - This healthcare index has a rolling price-to-earnings ratio of 31.8 times and has increased by 52.2% since its launch [8]
恒生创新药ETF（159316）今日获超2000万份净申购，关注创新药指数回调后投资机会
Sou Hu Cai Jing·2025-10-23 11:02